TOPLINE:

Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who switched androgen receptor pathway inhibitors (ARPI) after progressing on a first-line ARPI. However, the authors noted, the overall survival results "were likely confounded by the high rate of crossover" from a second-line ARPI to Lu-177-PSMA-617.

METHODOLOGY:

Patients with metastatic castration-resistant prostate cancer who progress on first-line ARPI therapy and are taxane-naive may receive an ARPI in the second-line setting if they are unable to tolerate taxane-based chemotherapy. However, an ARPI is not the most active treatment in this setting.

In the PSMAfore trial , researche

See Full Page